Skip to main content
PEPTARA LABS
Get Started

Glp-1 Receptor Agonists Explained

GLP-1 Receptor Agonists Explained

Published by · Updated · How we research and check our pages

The short answer

GLP-1 receptor agonists, explained simply, activate the GLP-1 receptor and produce four core effects: glucose-dependent insulin release, glucagon suppression, slower gastric emptying, and greater satiety (Frontiers in Endocrinology review, 2024, doi:10.3389/fendo.2024.1431292).

This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.

What are GLP-1 receptor agonists?

GLP-1 receptor agonists are a class of engineered molecules that bind and activate the glucagon-like peptide-1 receptor, copying a natural gut hormone that lowers blood sugar and reduces appetite (Frontiers in Endocrinology, 2024, doi:10.3389/fendo.2024.1431292).

GLP-1 is an incretin hormone the gut releases after eating. It tells the pancreas to release insulin, tells the liver to hold back glucagon, and signals the brain that you are full. GLP-1 receptor agonists are built to send that same signal, but stronger and for far longer than the natural hormone does (Frontiers in Endocrinology, 2024). The class now includes single-receptor agonists, dual agonists, and triple agonists, which differ by how many hormone receptors each drug hits.

How do GLP-1 receptor agonists work?

They activate the GLP-1 receptor and trigger four linked effects that together lower blood sugar and reduce food intake.

According to the 2024 Frontiers in Endocrinology review (doi:10.3389/fendo.2024.1431292), the main actions are:

1. Glucose-dependent insulin secretion. Insulin is released when blood sugar is high, which lowers the risk of overshooting into low blood sugar. 2. Glucagon suppression. Less glucagon means the liver makes less new glucose. 3. Slower gastric emptying. Food leaves the stomach more slowly, so fullness lasts longer. 4. Increased satiety. Signaling in appetite centers of the brain reduces hunger and food intake.

Dual and triple agonists layer more receptor targets on top of this. Tirzepatide also activates the GIP receptor (Jastreboff et al., 2022), and retatrutide activates the GIP and glucagon receptors as well (Jastreboff et al., 2023).

Why are GLP-1 receptor agonists engineered to resist breakdown?

Because native GLP-1 is destroyed within minutes, so these drugs are modified to survive far longer and act over days rather than seconds.

Natural GLP-1 is broken down almost immediately by an enzyme called DPP-4, which makes the raw hormone useless as a long-acting drug (Frontiers in Endocrinology, 2024). GLP-1 receptor agonists are engineered to resist that enzymatic degradation, for example by changing the molecule's structure or attaching it to carrier fragments that slow clearance. This slower clearance gives the engineered molecules a much longer duration of action than the natural hormone, which is why the class is described as long acting (Frontiers in Endocrinology, 2024).

What do the major GLP-1 trials report?

Large randomized trials report weight loss that tends to scale with the number of receptors a drug activates, and the newest triple agonist reports the largest reduction to date.

The table below lists each trial's design and reported outcome, with a source for each row. This is educational, not a prescription or a personal recommendation.

CompoundReceptor target(s)Key trialTrial designReported outcomeStatus
SemaglutideGLP-1STEP 1 (Wilding et al., 2021)One dose group vs placeboAbout 15% mean body weight loss (about -15.3 kg) vs about -2.6 kg placebo, 68 weeksApproved
TirzepatideGIP + GLP-1SURMOUNT-1 (Jastreboff et al., 2022)Three dose groups vs placeboUp to about 22.5% at 72 weeksApproved
RetatrutideGLP-1 + GIP + glucagonPhase 2 (Jastreboff et al., 2023)Several dose groups vs placeboUp to about 24.2% at 48 weeksInvestigational
SurvodutideGLP-1 + glucagonEarly trial (le Roux et al., 2024)Early-phase trialWeight loss reported in early trialsInvestigational

A head-to-head comparison exists inside the class. In SURPASS-2, a trial in people with type 2 diabetes, tirzepatide produced greater reductions than semaglutide (Frias et al., 2021). The differences between semaglutide, tirzepatide, and retatrutide in the table come from separate trials with different designs, so they are not a direct head-to-head result.

Approved or investigational: which GLP-1 drugs are which?

Semaglutide and tirzepatide carry regulatory approval for specified uses, while retatrutide and survodutide remain investigational and are not approved.

Approval status matters because it tells you whether a compound has cleared full regulatory review or is still being studied. Per FDA prescribing labels, semaglutide and tirzepatide have approved uses that include long-term weight management and blood glucose control. Retatrutide's data come from clinical studies, not approved use (Jastreboff et al., 2023). Survodutide is another investigational multi-receptor agonist with early trial data (le Roux et al., 2024). Investigational means the evidence is still being gathered and the compound has not been approved for general medical use.

Why does adding GIP and glucagon activity increase weight loss?

Trials suggest that hitting more than one metabolic receptor produces larger weight reductions, with the triple agonist reporting the highest figures so far.

Reading the trials in order shows the pattern. Semaglutide, which targets GLP-1 alone, reported about 15 percent (Wilding et al., 2021). Tirzepatide, which adds GIP, reported up to about 22.5 percent (Jastreboff et al., 2022). Retatrutide, which adds glucagon on top of GLP-1 and GIP, reported up to about 24.2 percent at 48 weeks (Jastreboff et al., 2023). The glucagon receptor is thought to raise energy expenditure, which may add to the appetite-lowering effect of the other two targets. This remains a cross-trial pattern rather than proof from a single study comparing all three.

What happens when someone stops a GLP-1 receptor agonist?

Research reports that much of the lost weight returns after stopping, so these drugs manage weight while taken rather than resetting it permanently.

In a STEP 1 extension, participants regained a large share of the weight they had lost within about a year of stopping semaglutide (Wilding et al., 2022). SURMOUNT-4 reported weight regain after tirzepatide was withdrawn (Aronne et al., 2024). Part of this reflects the body defending a higher weight: after weight loss, energy expenditure tends to fall through adaptive thermogenesis (Rosenbaum and Leibel, 2010). Weight loss on therapy also tends to slow to a plateau over time (Horn et al., 2025). Together these findings explain why the class is generally studied as ongoing therapy.

How are GLP-1 receptor agonists different from other research peptides?

They act on the incretin and glucagon receptor system, which is a different pathway from growth hormone secretagogues and amylin analogs.

Growth hormone secretagogues raise growth hormone and IGF-1 through a separate receptor. Examples with published data include MK-677, which raised fasting glucose and lowered insulin sensitivity in older adults (Nass et al., 2008), CJC-1295, which sustained higher GH and IGF-1 (Teichman et al., 2006), and ipamorelin, a selective GH secretagogue (Raun et al., 1998). Cagrilintide is an amylin analog studied alongside semaglutide (Lau et al., 2021); it targets amylin, not the GLP-1 receptor, so it is not itself a GLP-1 receptor agonist. Knowing which pathway a compound targets is the fastest way to place it in the right class.

Glp-1 Receptor Agonists Explained: FAQ

Are GLP-1 receptor agonists the same as peptides?

They are peptide-based or peptide-derived molecules built to target the GLP-1 receptor, engineered for stability so they resist rapid breakdown (Frontiers in Endocrinology, 2024, doi:10.3389/fendo.2024.1431292).

Is retatrutide approved?

No. Retatrutide is investigational. Its data, including up to about 24.2 percent weight loss at 48 weeks, come from clinical trials rather than approved use (Jastreboff et al., 2023).

Why does tirzepatide appear to outperform semaglutide?

In SURPASS-2, a head-to-head trial in people with type 2 diabetes, tirzepatide produced greater reductions than semaglutide (Frias et al., 2021). Tirzepatide activates both the GIP and GLP-1 receptors (Jastreboff et al., 2022).

Do people keep the weight off after stopping?

Research reports substantial regain. Participants regained much of the lost weight after stopping semaglutide (Wilding et al., 2022), and SURMOUNT-4 reported regain after tirzepatide was withdrawn (Aronne et al., 2024).

How did the major GLP-1 trials test their compounds?

STEP 1 compared one semaglutide dose with placebo (Wilding et al., 2021), and SURMOUNT-1 compared three tirzepatide dose groups with placebo (Jastreboff et al., 2022). These are trial designs reported as research data, not guidance.

Are there other multi-receptor agonists in development?

Yes. Survodutide, a GLP-1 and glucagon dual agonist, has early trial data and is investigational (le Roux et al., 2024).

What is the difference between GLP-1 and GIP?

Both are incretin hormones released after eating. GLP-1 only agonists target one receptor, while tirzepatide activates both the GIP and GLP-1 receptors (Jastreboff et al., 2022).

Sourcing research-grade peptides?

Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.

General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.

Chat with us